Circulating Angiogenic Factor Levels in Hypertensive Disorders of Pregnancy

NEJM Evid. 2022 Dec;1(12):EVIDoa2200161. doi: 10.1056/EVIDoa2200161. Epub 2022 Nov 9.

Abstract

Circulating Angiogenic Factor in Hypertension in PregnancyThis study measured serum soluble fms-like tyrosine kinase 1 to placental growth factor values in pregnant women hospitalized with hypertension. In women with a hypertensive disorder of pregnancy presenting between 23 and 35 weeks' gestation, a soluble fms-like tyrosine kinase 1:placental growth factor ratio ≥40 provided stratification of the risk of progressing to severe preeclampsia within 2 weeks.

MeSH terms

  • Angiogenesis Inducing Agents
  • Female
  • Humans
  • Hypertension, Pregnancy-Induced*
  • Placenta Growth Factor
  • Pre-Eclampsia*
  • Pregnancy
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factor Receptor-1

Substances

  • Placenta Growth Factor
  • Angiogenesis Inducing Agents
  • Vascular Endothelial Growth Factor Receptor-1
  • Vascular Endothelial Growth Factor A